Evolus Stock (NASDAQ:EOLS)
Previous Close
$11.99
52W Range
$9.29 - $17.82
50D Avg
$15.86
200D Avg
$13.73
Market Cap
$784.55M
Avg Vol (3M)
$624.99K
Beta
1.31
Div Yield
-
EOLS Company Profile
Evolus, Inc., a performance beauty company, provides medical aesthetic products for physicians and their patients in the United States. It offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults. The company was incorporated in 2012 and is headquartered in Newport Beach, California.
EOLS Performance
Peer Comparison
| Ticker | Company |
|---|---|
| SUPN | Supernus Pharmaceuticals, Inc. |
| ALKS | Alkermes plc |
| COLL | Collegium Pharmaceutical, Inc. |
| ANIP | ANI Pharmaceuticals, Inc. |
| PBH | Prestige Consumer Healthcare Inc. |
| AMPH | Amphastar Pharmaceuticals, Inc. |
| PCRX | Pacira BioSciences, Inc. |
| EGRX | Eagle Pharmaceuticals, Inc. |
| ITCI | Intra-Cellular Therapies, Inc. |
| PAHC | Phibro Animal Health Corporation |
| DCPH | Deciphera Pharmaceuticals, Inc. |